Processa Pharmaceuticals director granted 33,500 RSUs
Baluch Khoso reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Baluch Khoso reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Baluch Khoso received a grant of 33,500 Restricted Stock Units on 26 July 2026, each representing one share of common stock. The RSUs vested immediately but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, Khoso holds 38,749 RSUs, 12,000 stock options to buy common shares at $4.96, and 2,528 common shares directly, all reflecting a 1-for-25 reverse stock split completed in December 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 33,500 shares
Grant/Award
3 txns
Insider
Baluch Khoso
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F3 | 33,500 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F2, F3 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 38,749 contracts (Direct);
Stock Options (Right to Buy) — 12,000 contracts (Direct);
Common Stock — 2,528 shares (Direct)
Footnotes (3)
- F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
- F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Key Figures
RSUs granted: 33,500 units
RSUs held after grant: 38,749 units
Stock options underlying shares: 12,000 shares
+4 more
7 metrics
RSUs granted
33,500 units
Restricted Stock Units granted to director on 26 July 2026
RSUs held after grant
38,749 units
Total RSUs held by Baluch Khoso following the award
Stock options underlying shares
12,000 shares
Common shares underlying stock options held by Baluch Khoso
Option exercise price
$4.96 per share
Exercise price of stock options on Processa common stock
Common shares held
2,528 shares
Direct common stock holdings after reported transactions
Reverse split ratio
1-for-25
Reverse stock split effected on December 17, 2025
RSU payout deferral period
6 months
One trigger for RSU distribution is six months after the grant date
Key Terms
Restricted Stock Unit, Stock Options (Right to Buy), reverse stock split, change of control
4 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Options (Right to Buy) financial
"Security title reported as Stock Options (Right to Buy) on common stock"
reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
change of control regulatory
"distributed until the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Processa Pharmaceuticals (PCSA) report for Baluch Khoso?
Processa Pharmaceuticals reported that director Baluch Khoso received a grant of 33,500 Restricted Stock Units on 26 July 2026. Each RSU equals one common share, vesting immediately with distribution deferred until certain events such as termination or change of control.
How do the 33,500 RSUs granted by PCSA to Baluch Khoso vest and pay out?
The 33,500 RSUs granted to Baluch Khoso vested upon grant, so they are fully earned. However, they will not be distributed until the earlier of termination, the six-month anniversary of grant, a change of control, or his death, deferring actual share delivery.
What reverse stock split did Processa Pharmaceuticals (PCSA) implement that affects these holdings?
Processa Pharmaceuticals effected a 1-for-25 reverse stock split on 17 December 2025. All reported figures for RSUs, stock options, and common shares held by Baluch Khoso reflect this split-adjusted share count, as noted in the Form 4 footnotes.
Were the PCSA insider transactions for Baluch Khoso made under a Rule 10b5-1 trading plan?
The Rule 10b5-1 checkbox in the filing was not marked, so these transactions were not reported as occurring under a Rule 10b5-1 trading plan. The footnotes do not indicate any pre-arranged trading arrangement for this grant or the related holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
